Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

Apr 29, 2019

SELL
$216.71 - $338.96 $171,200 - $267,778
-790 Closed
0 $0
Q4 2018

Feb 12, 2019

SELL
$278.5 - $352.75 $6,962 - $8,818
-25 Reduced 3.07%
790 $238,000
Q2 2018

Jul 27, 2018

SELL
$257.52 - $306.91 $84,981 - $101,280
-330 Reduced 28.82%
815 $237,000
Q1 2018

May 14, 2018

SELL
$260.13 - $367.91 $72,836 - $103,014
-280 Reduced 19.65%
1,145 $314,000
Q4 2017

Jan 31, 2018

SELL
$307.64 - $344.58 $86,754 - $97,171
-282 Reduced 16.52%
1,425 $454,000
Q3 2017

Nov 08, 2017

BUY
$281.15 - $329.69 $479,923 - $562,780
1,707
1,707 $534,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $22.9B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Cypress Asset Management Inc Portfolio

Follow Cypress Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cypress Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cypress Asset Management Inc with notifications on news.